Detalhe da pesquisa
1.
Genomic landscape of patients in a phase II study of zanubrutinib in ibrutinib- and/or acalabrutinib-intolerant patients with B-cell malignancies.
Haematologica
; 2024 Jan 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38268449
2.
Extended evaluation of a phase 1/2 trial on dosing, safety, immunogenicity, and overall survival after immunizations with an advanced-generation Ad5 [E1-, E2b-]-CEA(6D) vaccine in late-stage colorectal cancer.
Cancer Immunol Immunother
; 64(8): 977-87, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-25956394
3.
Derazantinib alone and with atezolizumab in metastatic urothelial carcinoma with activating FGFR aberrations.
JNCI Cancer Spectr
; 8(3)2024 Apr 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-38627238
4.
Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients.
Cancer Immunol Immunother
; 62(8): 1293-301, 2013 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-23624851
5.
Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study.
Lancet Haematol
; 10(1): e35-e45, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36400069
6.
A Randomized, Phase II Trial of Cetuximab With or Without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients With Metastatic Colorectal Carcinoma.
Clin Colorectal Cancer
; 15(4): 337-344.e2, 2016 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-27118441